A small Cambridge biotech said Wednesday it has raised $85 million in fresh venture capital and appointed a pharmaceutical industry veteran chief executive as the startup works on potential treatments for fibrosis, the often deadly scarring of organs caused by a variety diseases.
Access the article on bostonglobe.com (paywall)